NCT01827930View on ClinicalTrials.gov

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response

PHASE3TerminatedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

January 1, 2017

Study Completion Date

January 1, 2017

Conditions
Leukemia, Myeloid, Chronic-Phase
Interventions
DRUG

Imatinib Mesylate 600 MG Oral Tablet

Imatinib Mesylate for CP CML

DRUG

Imatinib Mesylate 400 MG Oral Tablet

Imatinib Mesylate for CP CML

DRUG

Imatinib Mesylate

Imatinib Mesylate for CP CML

Trial Locations (1)

33000

Institut Bergonié, Bordeaux

Sponsors

Lead Sponsor

Institut Bergonié

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Institut Bergonié

OTHER